Herophilus is a San Francisco-based neurotherapeutics company focused on discovering novel drugs for complex neurological and psychiatric diseases. The company employs phenotypic screening, which involves observing the physical and biochemical characteristics of cells and tissues, to identify potential drug candidates. Herophilus combines human brain models, scaled biology, and machine learning to decode brain diseases from genetics to neural computation. This approach allows the company to gain deep biological insights and systematically develop drugs with greater therapeutic potential.

Herophilus serves clients in the pharmaceutical and biotechnology sectors, particularly those focused on neurological and psychiatric conditions. The company operates in the neurotherapeutics market, which aims to address the unmet medical needs of patients with brain diseases. Herophilus' business model revolves around drug discovery and development, partnering with other companies for clinical trials and commercialization. Revenue is generated through licensing agreements, research collaborations, and milestone payments.

Keywords: neurotherapeutics, phenotypic screening, brain models, machine learning, drug discovery, neurological diseases, psychiatric diseases, scaled biology, human brain organoids, therapeutic potential.